{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:19:35Z","timestamp":1790651975070,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biogen Japan"},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mitsubishi Tanabe"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Astellas"},{"name":"Takeda"},{"name":"Asahi Kasei Medical"},{"DOI":"10.13039\/501100002973","name":"Daiichi Sankyo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nihon Pharmaceutical"},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biogen Japan"},{"name":"Novartis Pharmaceuticals"},{"DOI":"10.13039\/100009539","name":"LSI Medience Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009539","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jneuroim.2020.577236","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:16:03Z","timestamp":1586279763000},"page":"577236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Risk factors of attacks in neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"343","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2020.577236_bb0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jneuroim.2017.12.019","article-title":"Chloride imbalance between serum and CSF in the acute phase of neuromyelitis optica","volume":"315","author":"Akaishi","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0010","first-page":"7","article-title":"Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence","author":"Akaishi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0015","first-page":"6,1930","article-title":"Chloride in intensive care units: a key electrolyte","author":"Bandak","year":"2017","journal-title":"F1000Research"},{"key":"10.1016\/j.jneuroim.2020.577236_bb0020","first-page":"471","article-title":"Expression and release of leptin and proinflammatory cytokines in patients with ulcerative colitis and infectious diarrhea","volume":"63","author":"Biesiada","year":"2012","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0025","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/acr.23107","article-title":"Relationship between neuromyelitis optica spectrum disorder and Sjogren\u2019s syndrome: central nervous system extraglandular disease or unrelated, co-occurring autoimmunity?","volume":"69","author":"Birnbaum","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0030","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0040","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12883-014-0200-5","article-title":"Sjogren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature","volume":"14","author":"Jayarangaiah","year":"2014","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0055","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0060","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0065","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0070","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001145","article-title":"The clinical characteristics of primary sjogren\u2019s syndrome with neuromyelitis optica spectrum disorder in China: a STROBE-compliant article","volume":"94","author":"Qiao","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jneuroim.2020.577236_bb0075","first-page":"7,128","article-title":"Changes in serum cytokines in response to musculoskeletal surgical trauma","author":"Reikeras","year":"2014","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.jneuroim.2020.577236_bb0080","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1212\/WNL.0b013e318296ea08","article-title":"Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders","volume":"80","author":"Sato","year":"2013","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0085","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2020.577236_bb0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820302137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820302137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:35:55Z","timestamp":1759048555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820302137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":18,"alternative-id":["S0165572820302137"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577236","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors of attacks in neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577236"}}